Study S001783

A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Dulaglutide on Retained Gastric Contents Using Gastric Ultrasound in Participants With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT07313813
Acronym: GBGT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 20
Start: 2025-12-29
Primary completion: 2026-08-13
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: DRUG:Dulaglutide
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:H9X-MC-GBGT

Registered primary outcomes

Percentage of Fasting Participants with Lack of Gastric Content Retention Post-Solid Test Meal [Day 116 (at 6, 8, 12, 18 and 24 hours after baseline or Day 115 solid test meal)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.